3Barrer-Arrema RG,Davidson WH,GoLdstein RJ,et al.Efficacy and safety of a nem HMG-CoA reductse inhibitor atorvastatin in patients with hypertrig Lyceridemia[J].J Am Med Soc,1996,275(2):128.
4Gotto A, Pownall H. Lipid - Regulation Drugs and Low - Density Lipoprotein Aaph - eresis Gotto A, Pownall H, Eds. Manual of Lipid Disorders. 2eded. Lippincott Williams & Wilkins, 1999. 292 ～ 328
5Bakker- Arkema RG, Davidson MH, Coldstein RJ, et al. Efficacy and safety of a new HMG - GoAreductase inhibitor, atrovastatin, in patients with hypertrigl yceridemia JAMA, 1996,275 (2): 128 ～ 133
6Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atrovastatin versus simvastatin, pravastatin, lovastatin, and fiuvastatin in patients with hypercholesterolemia (the CUPVES study). Am J Cardiol, 1998,81(5) :582 ～ 587
7Guan Y, Breyer MD. Peroxisome oroliferator - activated receptors (PPARs) :Novel theraputic targets in renal disease. Kidney Int,2001,60(1):14～30
8Taelsb, Dallongville J, Auwerx J,et al. Mechaniams of action of fibrate on lipid and lipoprotein metabolism. Circulation, 1998, 98 ( 19 ): 2088 ～ 2093
9Ruotolo G, Ericsson CG, Tettarmanti C, et al. Treatment effect on serumlipoprotine lipids, apolipoproteins and low density liporotine particle size and relationships of lipoprotine variables to progression of coronary artery disease in the Bezafibrate Cotonary Atherosclerosis Intervention Trial(BECAIT) [ J]. J Am Coll Cardiol, 1998,32:1648
10Morgan JM. Treamant and Effect of Niaspan, a Controlled - release Niacin,in Patients with Hypercholes terolemia is A Plcebo- controlled Trial.J Cardiovase Pharmacol Ther, 1996, (3): 195 ～ 202
